DK1224264T3 - Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser - Google Patents

Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser

Info

Publication number
DK1224264T3
DK1224264T3 DK00970961.9T DK00970961T DK1224264T3 DK 1224264 T3 DK1224264 T3 DK 1224264T3 DK 00970961 T DK00970961 T DK 00970961T DK 1224264 T3 DK1224264 T3 DK 1224264T3
Authority
DK
Denmark
Prior art keywords
cells
cell lines
immune responses
presenting cells
allogeneic cell
Prior art date
Application number
DK00970961.9T
Other languages
English (en)
Inventor
Jacques F Banchereau
Frederic Berard
Patrick Blanco
Eve-Marie Neidhart-Berard
Mahyar Nouri-Shirazi
Anna Karolina Palucka
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Application granted granted Critical
Publication of DK1224264T3 publication Critical patent/DK1224264T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464494—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK00970961.9T 1999-10-15 2000-10-16 Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser DK1224264T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15990399P 1999-10-15 1999-10-15
PCT/US2000/028670 WO2001029192A2 (en) 1999-10-15 2000-10-16 Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses

Publications (1)

Publication Number Publication Date
DK1224264T3 true DK1224264T3 (da) 2010-05-10

Family

ID=22574604

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00970961.9T DK1224264T3 (da) 1999-10-15 2000-10-16 Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser

Country Status (10)

Country Link
US (2) US7988963B1 (da)
EP (3) EP2151245A1 (da)
AT (1) ATE456649T1 (da)
AU (1) AU8026800A (da)
CY (1) CY1110235T1 (da)
DE (1) DE60043781D1 (da)
DK (1) DK1224264T3 (da)
ES (1) ES2340358T3 (da)
PT (1) PT1224264E (da)
WO (1) WO2001029192A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040022813A1 (en) * 2002-08-05 2004-02-05 Jean-Claude Bystryn Shed antigen vaccine with dendritic cells adjuvant
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
WO2010068680A1 (en) * 2008-12-10 2010-06-17 Mount Sinai School Of Medicine Of New York University Thelper cell type 17 lineage-specific adjuvants, compositions and methods
CN103957925A (zh) 2011-10-20 2014-07-30 加利福尼亚干细胞公司 具有γ干扰素的抗原呈递癌症疫苗
WO2016145578A1 (en) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
EP3468581A1 (en) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
JP7146732B2 (ja) 2016-07-13 2022-10-04 オハイオ ステート イノベーション ファウンデーション 宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法
CN111432836A (zh) 2017-09-05 2020-07-17 转矩医疗股份有限公司 治疗性蛋白质组合物及其制备和使用方法
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
EP0633929B1 (en) 1992-04-01 2004-03-03 The Rockefeller University METHOD FOR $i(IN VITRO) PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
WO1995032734A1 (en) 1994-05-26 1995-12-07 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness
US6300090B1 (en) * 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
JP2000505650A (ja) * 1996-02-08 2000-05-16 アメリカ合衆国 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物
WO1998052582A2 (en) * 1997-05-23 1998-11-26 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment
AU2872199A (en) * 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
AU2002953094A0 (en) * 2002-12-04 2002-12-19 The University Of Queensland Immunomodulating compositions, processes for their production and uses therefor

Also Published As

Publication number Publication date
EP1224264A2 (en) 2002-07-24
US7988963B1 (en) 2011-08-02
US20110268767A1 (en) 2011-11-03
EP1224264B1 (en) 2010-01-27
PT1224264E (pt) 2010-03-15
ATE456649T1 (de) 2010-02-15
CY1110235T1 (el) 2015-01-14
WO2001029192A2 (en) 2001-04-26
AU8026800A (en) 2001-04-30
EP2151245A1 (en) 2010-02-10
ES2340358T3 (es) 2010-06-02
DE60043781D1 (de) 2010-03-18
EP2302038A1 (en) 2011-03-30
WO2001029192A3 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
von Spee-Mayer et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus
Stockinger et al. CD4+ memory T cells: functional differentiation and homeostasis
Yoshida et al. Poly (lactic‐co‐glycolic acid) enhances maturation of human monocyte‐derived dendritic cells
HK1086750A1 (en) Pharmaceutical composition for inducing an immune response in a human or animal
DK1224264T3 (da) Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
BR9610802A (pt) Método para melhoria da resposta imunológica método de preparo de células t de antígeno específico método para induzir tolerância de tecido de enxerto auxiliar de vacina meio de expansão e preparação de células dentríticas população de células dentríticas e respectivo método de preparo método para direcionar células-tronco hematopoiéticas ou células progenitoras a uma linhagem de células dentríticas
DK1739166T3 (da) Fremstilling af fødevare- eller autoantigen-specifikke Tr1-celler fra en leukocyt- eller PBMC-population
DK0463151T3 (da) Frembringelse af xenogene antistoffer
NO986173L (no) FremgangsmÕte for aktivering av dendrittceller
Baruah et al. Mice lacking C1q or C3 show accelerated rejection of minor H disparate skin grafts and resistance to induction of tolerance
Carpentier et al. Extrathymic induction of Foxp3+ regulatory T cells declines with age in a T‐cell intrinsic manner
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
Romano et al. Isolation and expansion of thymus‐derived regulatory T cells for use in pediatric heart transplant patients
Wrammert et al. Human immune memory to yellow fever and smallpox vaccination
WO2003000199A3 (en) Ilt3 and ilt4-related compositions and methods
Karsten et al. Biologic meshes and synthetic meshes in cancer patients: a double-edged sword: differences in production of IL-6 and IL-12 caused by acellular dermal matrices in human immune cells
WO2001094551A3 (de) Gen-modifizierte t-zellen, verfahren zu ihrer herstellung und ihre verwendung
Szabolcs The immunobiology of cord blood transplantation
e Sousa et al. Conditioning of dendritic cells by pathogen-derived stimuli
Bieńkowska et al. Thymus-deriving natural regulatory T cell generation in vitro: Role of the source of activation signals
Pawelec et al. Engineering anticancer T cells for extended functional longevity
WO2001028574A3 (en) Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain
Kronenberg et al. Do mucosal T cells prevent intestinal inflammation?
Maksymowicz et al. Repopulation of donor heart by recipient bone marrow–derived dendritic cells prior to transplantation causes acute rejection by both the allogeneic and syngeneic recipient